Logo image of BIO3.DE

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) Stock Price, Quote, News and Overview

FRA:BIO3 - Deutsche Boerse Ag - DE0005227235 - Currency: EUR

30  0 (0%)

BIO3.DE Quote, Performance and Key Statistics

BIOTEST AG-VORZUGSAKTIEN

FRA:BIO3 (4/14/2025, 2:07:12 PM)

30

0 (0%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High39.8
52 Week Low25
Market Cap1.19B
Shares39.57M
Float570.00K
Yearly Dividend0
Dividend YieldN/A
PE17.54
Fwd PE19.8
Earnings (Next)05-05 2025-05-05
IPO10-14 1987-10-14


BIO3.DE short term performance overview.The bars show the price performance of BIO3.DE in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

BIO3.DE long term performance overview.The bars show the price performance of BIO3.DE in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15 -20

The current stock price of BIO3.DE is 30 EUR. In the past month the price increased by 11.11%. In the past year, price decreased by -23.66%.

BIOTEST AG-VORZUGSAKTIEN / BIO3 Daily stock chart

BIO3.DE Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.12 285.34B
AMG.DE AMGEN INC 14.06 131.64B
GIS.DE GILEAD SCIENCES INC 22.38 112.98B
VX1.DE VERTEX PHARMACEUTICALS INC 1728.6 111.10B
ARGX.BR ARGENX SE 352.5 32.72B
22UA.DE BIONTECH SE-ADR N/A 24.57B
IDP.DE BIOGEN INC 7.29 15.44B
0QF.DE MODERNA INC N/A 9.46B
1MRNA.MI MODERNA INC N/A 9.08B
BIO.DE BIOTEST AG 24.8 1.68B
GLPG.AS GALAPAGOS NV N/A 1.54B
AZT.OL ARCTICZYMES TECHNOLOGIES ASA 124.29 888.62M

About BIO3.DE

Company Profile

BIO3 logo image Biotest AG is a DE-based company operating in Biotechnology industry. The company is headquartered in Dreieich, Hessen. Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. The company develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.

Company Info

BIOTEST AG-VORZUGSAKTIEN

Landsteinerstr. 5

Dreieich HESSEN DE

Employees: 2464

Company Website: https://www.biotest.com/

Phone: 4961038010

BIOTEST AG-VORZUGSAKTIEN / BIO3.DE FAQ

What is the stock price of BIOTEST AG-VORZUGSAKTIEN today?

The current stock price of BIO3.DE is 30 EUR.


What is the ticker symbol for BIOTEST AG-VORZUGSAKTIEN stock?

The exchange symbol of BIOTEST AG-VORZUGSAKTIEN is BIO3 and it is listed on the Deutsche Boerse Ag exchange.


On which exchange is BIO3.DE stock listed?

BIO3.DE stock is listed on the Deutsche Boerse Ag exchange.


What is BIOTEST AG-VORZUGSAKTIEN worth?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a market capitalization of 1.19B EUR. This makes BIO3.DE a Small Cap stock.


How many employees does BIOTEST AG-VORZUGSAKTIEN have?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) currently has 2464 employees.


What are the support and resistance levels for BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) has a support level at 28.13 and a resistance level at 30.01. Check the full technical report for a detailed analysis of BIO3.DE support and resistance levels.


Is BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) expected to grow?

The Revenue of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is expected to decline by -6.17% in the next year. Check the estimates tab for more information on the BIO3.DE EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) stock pay dividends?

BIO3.DE does not pay a dividend.


When does BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) report earnings?

BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) will report earnings on 2025-05-05.


What is the Price/Earnings (PE) ratio of BIOTEST AG-VORZUGSAKTIEN (BIO3.DE)?

The PE ratio for BIOTEST AG-VORZUGSAKTIEN (BIO3.DE) is 17.54. This is based on the reported non-GAAP earnings per share of 1.71 and the current share price of 30 EUR. Check the full fundamental report for a full analysis of the valuation metrics for BIO3.DE.


BIO3.DE Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BIO3.DE. When comparing the yearly performance of all stocks, BIO3.DE is a bad performer in the overall market: 83.56% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIO3.DE Fundamental Analysis

ChartMill assigns a fundamental rating of 5 / 10 to BIO3.DE. BIO3.DE has only an average score on both its financial health and profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO3.DE Financial Highlights

Over the last trailing twelve months BIO3.DE reported a non-GAAP Earnings per Share(EPS) of 1.71. The EPS increased by 32.71% compared to the year before.


Industry RankSector Rank
PM (TTM) 23.75%
ROA 13.97%
ROE 35.86%
Debt/Equity 0.8
Chartmill High Growth Momentum
EPS Q2Q%-108.65%
Sales Q2Q%-40.39%
EPS 1Y (TTM)32.71%
Revenue 1Y (TTM)-8.51%

BIO3.DE Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 46% to BIO3.DE. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -103.15% and a revenue growth -6.17% for BIO3.DE


Ownership
Inst Owners0.21%
Ins OwnersN/A
Short Float %N/A
Short RatioN/A
Analysts
Analysts45.71
Price TargetN/A
EPS Next Y-103.15%
Revenue Next Year-6.17%